Many of us in the United States with advanced prostate cancer who have failed Zytiga are looking to enter the Early Access MDV-3100 Clinical Trial. However, you need to be aware that there are some requirements you will need to meet prior to starting MDV-3100.
You will need to wait 30 days after stopping Zytiga to allow it to “washout” of your system. Additionally, if you have had any radiation treatments you must wait 3 weeks after the treatment before you will be allowed to have the MDV-3100.
As with all trials there are a large number of forms that will be needed to be filled out and signed. The forms will need to be completed within 28 days of your receiving them, you will need your blood drawn to check your liver and kidney functions and have an EKG.
If you are interested in the trial, have advanced castrate resistant prostate cancer, you should contact the trial site immediately and get the ball rolling so you will be able to start the trial ASAP after you have completed the forms and gone through any required “wash out” periods.
A list of the trial sites and the specific contact information can be found on this blog at:
Joel T Nowak, M.A., M.S.W.
Failing Zytiga – Will MDV3100 have any chance of working ?
The criterea for failing Zytiga is a > 25% increase in PSA combined with radiological progression of bone metastasis.
This means that the tumour has escaped total androgen ablation with Zytiga and has mutated to a hormone independent phenotype. In other words the cancer has become androgen independent and this raises the question as to whether an antiandrogen such as Enzalutamide (MDV 3100) will even work post Zytiga.
With the tumour progression post Zytiga involving metastasis a better approach for Zytiga refractory treatment would be to target the metastatic growth by use of an antimetastatic agent such as Salvestrol which targets the CYP1B1 enzyme, or another promising agent Cabozantinib which targets the VEGFR and Met kinases.